Current Landscape and Future Direction of PD-1/PD-L1 Checkpoint Inhibitors in Cancer Treatment

被引：2
作者：
Serrati, Simona [1 ]
Margheri, Francesca [2 ]
机构：
[1] IRCCS Ist Tumori Giovanni Paolo II, Lab Expt Pharmacol, I-70124 Bari, Italy
[2] Univ Florence, Dept Expt & Clin Biomed Sci, I-50134 Florence, Italy
来源：
BIOMOLECULES | 2023年 / 13卷 / 08期
关键词：
IMMUNE; RESISTANCE;
D O I：
10.3390/biom13081209
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Herpes zoster in patients with lung cancer treated with PD-1/PD-L1 antibodies
    Nagai, Yoshiaki
    Sata, Masafumi
    Ohta, Hiromitsu
    Onuki, Tsugitoshi
    Saito, Tatsuya
    Uchiyama, Ayumi
    Kurosaki, Ayako
    Yoshizumi, Naoko
    Takigami, Ayako
    Nakazawa, Shoko
    Nakayama, Masayuki
    Yamaguchi, Hironori
    Hagiwara, Koichi
    [J]. IMMUNOTHERAPY, 2022, 14 (15) : 1211 - 1217
  • [32] Combination of PD-L1 and PVR determines sensitivity to PD-1 blockade
    Lee, Bo Ryeong
    Chae, Sehyun
    Moon, Jihyun
    Kim, Myeong Joon
    Lee, Hankyu
    Ko, Hyuk Wan
    Cho, Byoung Chul
    Shim, Hyo Sup
    Hwang, Daehee
    Kim, Hye Ryun
    Ha, Sang-Jun
    [J]. JCI INSIGHT, 2020, 5 (14)
  • [33] 1,5-Disubstituted tetrazoles as PD-1/PD-L1 antagonists
    van der Straat, Robin
    Draijer, Rosalie
    Surmiak, Ewa
    Butera, Roberto
    Land, Lennart
    Magiera-Mularz, Katarzyna
    Musielak, Bogdan
    Plewka, Jacek
    Holak, Tad A.
    Domling, Alexander
    [J]. RSC MEDICINAL CHEMISTRY, 2024, 15 (04): : 1210 - 1215
  • [34] Targeted Glucose or Glutamine Metabolic Therapy Combined With PD-1/PD-L1 Checkpoint Blockade Immunotherapy for the Treatment of Tumors - Mechanisms and Strategies
    Ma, Guofeng
    Li, Chun
    Zhang, Zhilei
    Liang, Ye
    Liang, Zhijuan
    Chen, Yuanbin
    Wang, Liping
    Li, Dan
    Zeng, Manqin
    Shan, Wenhong
    Niu, Haitao
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [35] Controlling Nutritional Status (CONUT) Predicts Survival in Gastric Cancer Patients With Immune Checkpoint Inhibitor (PD-1/PD-L1) Outcomes
    Chen, Li
    Sun, Hao
    Zhao, Ruihu
    Huang, Rong
    Pan, Hongming
    Zuo, Yanjiao
    Zhang, Lele
    Xue, Yingwei
    Li, Xingrui
    Song, Hongjiang
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [36] Gastric Inflammatory Prognostic Index (GIPI) in Patients with Metastatic Gastro-Esophageal Junction/Gastric Cancer Treated with PD-1/PD-L1 Immune Checkpoint Inhibitors
    Formica, Vincenzo
    Morelli, Cristina
    Patrikidou, Anna
    Murias, Carmen
    Butt, Sabeeh
    Nardecchia, Antonella
    Lucchetti, Jessica
    Renzi, Nicola
    Shiu, Kai-Keen
    Roselli, Mario
    Arkenau, Hendrik-Tobias
    [J]. TARGETED ONCOLOGY, 2020, 15 (03) : 327 - 336
  • [37] Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
    Yin, Zi
    Yu, Min
    Ma, Tingting
    Zhang, Chuanzhao
    Huang, Shanzhou
    Karimzadeh, Mohammad Reza
    Momtazi-Borojeni, Amir Abaas
    Chen, Sheng
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (01)
  • [38] Design, Synthesis, and Biological Evaluation of Imidazopyridines as PD-1/PD-L1 Antagonists
    Butera, Roberto
    Wazynska, Marta
    Magiera-Mularz, Katarzyna
    Plewka, Jacek
    Musielak, Bogdan
    Surmiak, Ewa
    Sala, Dominik
    Kitel, Radoslaw
    de Bruyn, Marco
    Nijman, Hans W.
    Elsinga, Philip H.
    Holak, Tad A.
    Domling, Alexander
    [J]. ACS MEDICINAL CHEMISTRY LETTERS, 2021, 12 (05): : 768 - 773
  • [39] Hyperprogressive disease in non-small cell lung cancer after PD-1/PD-L1 inhibitors immunotherapy: underlying killer
    Li, Yanping
    Chen, Tianhong
    Nie, Tian Yi
    Han, Juyuan
    He, Yunyan
    Tang, Xingxing
    Zhang, Li
    [J]. FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [40] Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
    Chu, Xianjing
    Tian, Wentao
    Wang, Ziqi
    Zhang, Jing
    Zhou, Rongrong
    [J]. MOLECULAR CANCER, 2023, 22 (01)
12345